89BIO (ETNB) Competitors $9.36 +0.26 (+2.86%) Closing price 04:00 PM EasternExtended Trading$9.36 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. AXSM, CRSP, ABVX, MRUS, CYTK, VKTX, TGTX, KRYS, ACAD, and PCVXShould you be buying 89BIO stock or one of its competitors? The main competitors of 89BIO include Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Abivax (ABVX), Merus (MRUS), Cytokinetics (CYTK), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. 89BIO vs. Its Competitors Axsome Therapeutics CRISPR Therapeutics Abivax Merus Cytokinetics Viking Therapeutics TG Therapeutics Krystal Biotech ACADIA Pharmaceuticals Vaxcyte 89BIO (NASDAQ:ETNB) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Which has better valuation and earnings, ETNB or AXSM? Axsome Therapeutics has higher revenue and earnings than 89BIO. Axsome Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.61-2.59Axsome Therapeutics$385.69M15.67-$287.22M-$5.07-23.90 Is ETNB or AXSM more profitable? 89BIO has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -49.88%. 89BIO's return on equity of -94.48% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -94.48% -80.92% Axsome Therapeutics -49.88%-283.22%-33.06% Do institutionals and insiders hold more shares of ETNB or AXSM? 81.5% of Axsome Therapeutics shares are held by institutional investors. 2.6% of 89BIO shares are held by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend ETNB or AXSM? 89BIO presently has a consensus target price of $26.63, suggesting a potential upside of 184.46%. Axsome Therapeutics has a consensus target price of $178.00, suggesting a potential upside of 46.93%. Given 89BIO's higher probable upside, analysts plainly believe 89BIO is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the media favor ETNB or AXSM? In the previous week, Axsome Therapeutics had 9 more articles in the media than 89BIO. MarketBeat recorded 15 mentions for Axsome Therapeutics and 6 mentions for 89BIO. Axsome Therapeutics' average media sentiment score of 1.42 beat 89BIO's score of 0.89 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 89BIO 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ETNB or AXSM? 89BIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. SummaryAxsome Therapeutics beats 89BIO on 9 of the 16 factors compared between the two stocks. Get 89BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.39B$3.09B$5.74B$9.77BDividend YieldN/A2.24%4.40%4.08%P/E Ratio-2.5920.7830.4126.04Price / SalesN/A347.65428.97104.72Price / CashN/A43.2325.7828.79Price / Book2.809.809.706.08Net Income-$367.08M-$54.08M$3.27B$265.64M7 Day Performance4.00%4.93%3.94%3.11%1 Month Performance-2.40%3.64%3.81%0.39%1 Year Performance0.38%8.20%31.26%18.52% 89BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89BIO2.15 of 5 stars$9.36+2.9%$26.63+184.5%+2.8%$1.39BN/A-2.5940News CoverageAnalyst ForecastAXSMAxsome Therapeutics4.8215 of 5 stars$111.13+1.8%$178.00+60.2%+32.2%$5.45B$385.69M0.00380News CoveragePositive NewsCRSPCRISPR Therapeutics3.6343 of 5 stars$57.59-3.6%$71.60+24.3%+11.2%$5.43B$37.31M0.00460Positive NewsABVXAbivax2.7577 of 5 stars$70.01-0.6%$92.33+31.9%+567.8%$5.32BN/A0.0061Positive NewsMRUSMerus2.3403 of 5 stars$66.00-1.9%$88.50+34.1%+22.7%$5.09B$36.13M0.0037News CoverageAnalyst ForecastCYTKCytokinetics3.7035 of 5 stars$38.95+0.7%$71.58+83.8%-35.4%$4.63B$18.47M-7.64250VKTXViking Therapeutics3.9465 of 5 stars$42.09+5.1%$86.92+106.5%-60.0%$4.50BN/A-27.5120TGTXTG Therapeutics4.4045 of 5 stars$27.73-1.2%$46.25+66.8%+16.6%$4.46B$329M74.95290Positive NewsKRYSKrystal Biotech4.7054 of 5 stars$146.30-2.6%$210.75+44.1%-27.2%$4.35B$290.52M30.54210ACADACADIA Pharmaceuticals4.0198 of 5 stars$25.06-1.1%$28.88+15.2%+58.8%$4.27B$957.80M18.84510Positive NewsPCVXVaxcyte2.4039 of 5 stars$32.09-1.9%$136.50+325.4%-61.6%$4.25BN/A0.00160Positive News Related Companies and Tools Related Companies Axsome Therapeutics Alternatives CRISPR Therapeutics Alternatives Abivax Alternatives Merus Alternatives Cytokinetics Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives Krystal Biotech Alternatives ACADIA Pharmaceuticals Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access